ARCHIVES

Secondary AML In High-Dose Chemo Trial Cause For Careful Monitoring, NCI Says

This article is from The Cancer Letter archive.

Vol. 20 No. 33 | August 19, 1994

Download PDF Visit The Full Archive

Related Articles

Prevention Program Being Developed For Primary Providers

January 29, 1988

House Passes Bill Giving FDA Authority Over Tobacco Products

April 10, 2009

Impact Of DRGs On Clinical Research Less Than First Feared, Speakers Tell NIH Directors Meeting

June 20, 1986

Cancer Panel To Examine Health Of Phase I Trials

May 17, 1996

ACS Reorganization Plans, Policy Changes Discussed By Board

November 29, 1991

Cancer Policy: Coffey Letter Lists Research Initiatives That Justify Increase

December 19, 1997